Strong data from the ROADS clinical trial highlight the potential of GammaTile® cesium-131 collagen tile-based radiation therapy (TBRT) to improve outcomes for patients with brain metastases requiring surgery. In the multicenter Phase 3 study, immediate placement of tile-based radiation during surgery resulted in significantly lower rates of tumor regrowth, a greater likelihood of living longer without recurrence, and significantly improved overall survival compared to standard of care, without increased side effects. These findings, published as a Rapid Communication in the Journal of Clinical Oncology, reinforce the value of delivering targeted radiation therapy at the time of surgery. Based on the results, the study authors conclude that GammaTile should be considered a standard-of-care option for patients with newly diagnosed operable brain metastases. Read the press release: na2.hubs.ly/H083mDx0 #ROADSTrial #GammaTile #JCO @JCO_ASCO See full prescribing information at na2.hubs.ly/H083mDy0

Hear from radiation oncologist and GammaTile practitioner Dr. Lindsey Sloan on M Health Fairview University of Minnesota Medical Center’s designation as a GammaTile Center of Excellence this past March. Lindsey Sloan, MD, PhD, is an Associate Professor in Radiation Oncology and a radiobiologist at the Masonic Cancer Center. She leads the Sloan Laboratory within the University of Minnesota Brain Tumor Program and serves on the faculty of the University of Minnesota Medical School. #GammaTileCOE See full prescribing information at na2.hubs.ly/H08tc7K0

Are you attending #2026CNS? Join us at one of our educational events to hear how GammaTile is improving tumor control in operable brain tumors. Explore the GammaTile schedule: na2.hubs.ly/H08rtz50 See full prescribing information at na2.hubs.ly/H08rtxV0

GammaTile achieved 98.7% local tumor control by 12 months, compared to 84.6% for standard of care, reducing the risk of local tumor recurrence at 12 months by more than 90% (HR: 0.07, 95% CI: 0.01–0.56; p=0.012)1* In the manuscript's conclusion, the study authors state that GammaTile should be considered a standard-of-care option for patients with newly diagnosed brain metastases. Read the publication: na2.hubs.ly/H08q1gf0 Reference: Weinberg JS, Imber BS, DiNapoli V, et al. J Clin Oncol. 2026. *Local control calculated as 100% minus the cumulative incidence of surgical bed recurrence (SBR) expressed as a percentage. See full prescribing information at na2.hubs.ly/H08q1gg0

At #ASTRO26, we invited attendees for an evening on the waterfront to learn more about the ROADS RCT data and best practices for tile-based radiation therapy integration.   The GammaTile team welcomed Lindsey Sloan, MD, PhD, and M. Sean Peach, MD, PhD, to present how Tile-Based Radiation Therapy (TBRT) with GammaTile is revolutionizing treatment timing and local control by closing the treatment gap.   Thank you to everyone who joined us for an evening of great conversation, and to Drs. Sloan and Peach for sharing their insights. We’re eager to keep the momentum going as we work together to close the treatment gap for patients with operable brain tumors.

We are proud to announce Columbia University Irving Medical Center/New York-Presbyterian Hospital as our latest GammaTile Center of Excellence, acknowledging their outstanding clinical expertise in the GammaTile procedure. The following physicians have received this designation: - Brian J.A. Gill, MD, Neurological Surgeon - Michael B. Sisti, MD, Neurological Surgeon - Tony Wang, MD, Radiation Oncologist Read the press release: na2.hubs.ly/H08m2wv0 See full prescribing information at na2.hubs.ly/H08m2ww0

St. Luke's Boise Medical Center has been named our newest GammaTile Center of Excellence, recognizing their expertise in the GammaTile procedure and commitment to advancing brain tumor treatment. The following physicians have received this designation: - Edward A. Duckworth, MD - David P. Bray, MD - Derek L. Martinez, MD - Benjamin G. McGahan, MD - Cameron S. Thorpe, MD - Tonya L. Kuhn, MD - Stephen C. Smith, MD - Timothy E. Sawyer, MD - Amy Geyer, MS Read the press release: na2.hubs.ly/H08dxTr0 #GammaTile #GammaTileCOE See full prescribing information at na2.hubs.ly/H08dxSR0

Are you attending #ASTRO26? Our GammaTile Clinical Dinner Symposium, “Closing the Treatment Gap: How the ROADS Data is Revolutionizing the Future of Operable Brain Tumor Radiation Therapy,” takes place tomorrow, September 27th Reserve your spot: na2.hubs.ly/H081r_m0 Lindsey Sloan, MD, PhD, is an Associate Professor in Radiation Oncology and a radiobiologist at the Masonic Cancer Center. She leads the Sloan Laboratory within the University of Minnesota Brain Tumor Program and serves on the faculty of the University of Minnesota Medical School. M. Sean Peach, MD, PhD, is an Associate Professor at The Brody School of Medicine at East Carolina University and Director of Brachytherapy Services at ECU Health. See full prescribing information at na2.hubs.ly/H081r-X0

#ASTRO26 is two days away. Join the GammaTile team at 12 PM this Sunday, September 27th, for an Industry Expert Theater, “Improved Local Control and Survival: Phase 3 Evidence for Tile-Based Radiation in Brain Metastases.” Add to calendar: na2.hubs.ly/H081hMS0 Brandon Imber, MD, MA, is an Assistant Attending Radiation Oncologist at Memorial Sloan Kettering Cancer Center. Lindsey Sloan, MD, PhD, is an Associate Professor in Radiation Oncology and a radiobiologist at the Masonic Cancer Center. She leads the Sloan Laboratory within the University of Minnesota Brain Tumor Program and serves on the faculty of the University of Minnesota Medical School. See full prescribing information at na2.hubs.ly/H081hMT0

Are you heading to Boston, MA, for #ASTRO26 this weekend? Our GammaTile Clinical Dinner Symposium, “Closing the Treatment Gap: How the ROADS Data is Revolutionizing the Future of Operable Brain Tumor Radiation Therapy,” takes place this Sunday, September 27th. Reserve your spot: na2.hubs.ly/H07-l9Y0 See full prescribing information at na2.hubs.ly/H07-l9Z0

#ASTRO26 kicks off this weekend. Join the GammaTile team at 12 PM this Sunday, September 27th, for an Industry Expert Theater, “Improved Local Control and Survival: Phase 3 Evidence for Tile-Based Radiation in Brain Metastases.” Add to calendar: na2.hubs.ly/H07Zkng0 Note: The Industry Expert Theater content and views expressed therein are those of the Exhibitor and not of ASTRO. See full prescribing information at na2.hubs.ly/H07Zknh0

#ASTRO26 is right around the corner. Mark your calendars for 12 PM on Sunday, September 27th, to join us for an Industry Expert Theater, titled “Improved Local Control and Survival: Phase 3 Evidence for Tile-Based Radiation in Brain Metastases.” Add to calendar: na2.hubs.ly/H07Q99_0 See full prescribing information at na2.hubs.ly/H07Q9b10

Join us for a beverage break during “SYM10A: Brain Tumor Update - Management of Malignant Brain Tumors,” to learn more about GammaTile at the Congress of Neurological Surgeons (@CNS_Update) 2026 Annual Meeting this November! Add to calendar: na2.hubs.ly/H07L8yP0 See full prescribing information at na2.hubs.ly/H07L8yQ0

Hear from Dr. Suchit Patel, Radiation Oncologist at Renown Regional Medical Center, on the importance of providing quality brain tumor care close to home, so patients can get the treatment they need without having to travel far. Read Renown Regional Medical Center’s COE Press Release: na2.hubs.ly/H07K0CP0 #GammaTile #GammaTileCOE See full prescribing information at na2.hubs.ly/H07K0CS0

Space is limited for our #ASTRO26 Clinical Symposium, “Closing the Treatment Gap: How the ROADS Data is Revolutionizing the Future of Operable Brain Tumor Radiation Therapy.” Join us on the waterfront for a candid look at the ROADS RCT data and best practices for TBRT integration. Reserve your spot: na2.hubs.ly/H07HTTn0 See full prescribing information at na2.hubs.ly/H07HTYG0

GammaTile is the first and only tile-based radiation therapy (TBRT) for the treatment of operable brain tumors. Implanted directly into the tumor cavity at the time of resection, GammaTile immediately starts delivering a targeted therapeutic dose to possible remaining tumor cells. The collagen tile keeps the radiation source away from healthy tissue, reducing the risk of radiation side effects. Learn more about how GammaTile works for the treatment of operable brain tumors: na2.hubs.ly/H07FkV70 See full prescribing information at na2.hubs.ly/H07FkVw0 Reference: Kutuk T, et al. Brachytherapy. 23(6):751-760 (2024).

Renown Regional Medical Center is the latest addition to the GammaTile Center of Excellence Program! This Reno-based center has demonstrated an outstanding dedication to clinical expertise and patient education for patients with operable brain tumors. The following physicians have received this recognition: • Suchit Patel, MD, PhD • Garrett Green, MD • Rima Rindler, MD • Angelique Tay, MD • Michael Moore, MD • Chris Demers, MD Read the press release: na2.hubs.ly/H07BnKb0 #GammaTileCOE #GammaTile See full prescribing information at na2.hubs.ly/H07Bn5Y0

Space is limited for our #ASTRO26 Clinical Dinner Symposium, “Closing the Treatment Gap: How the ROADS Data is Revolutionizing the Future of Operable Brain Tumor Radiation Therapy.” Join us on the waterfront for a candid look at the ROADS RCT data and best practices for TBRT integration. Reserve your spot: na2.hubs.ly/H07zvJH0 See full prescribing information at na2.hubs.ly/H07zxr20